Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Boston Scientific Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Boston Scientific Corporation trades at $44.53 (market cap $67.33B). The key difference: Boston Scientific Corporation is far larger — about 15× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| ACAD | BSX | |
|---|---|---|
Market Cap | $4.49B | $67.33B |
Sector | Health | Health |
52-Week High | $28.06 | $108.14 |
52-Week Low | $20.06 | $42.68 |
Enterprise Value | $3.69B | $76.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Boston Scientific (BSX) trades at $45.30, showing modest daily gains of 0.35% amid a bearish technical trend. The company demonstrates strong fundamentals with consistent earnings beats, revenue growth from $12.7B in 2022 to $20.1B in 2025, and robust profitability margins. Recent news highlights a significant price decline from all-time highs, creating valuation opportunities despite competitive pressures in key segments like electrophysiology.
The investment outlook remains positive based on strong analyst consensus (88% buy ratings) and a $73.63 price target implying 63% upside. Key risks include growth deceleration in core products and market volatility. Fundamentals support long-term value, but investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
